Bifogade filer
Invitation to Guard Therapeutics’ R&D Update on January 30
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Guard Therapeutics [GUARD], a biotechnology company specialized in kidney diseases, announced today that the company is organizing a digital R&D Update on January 30, 2024, from 14:00 to 15:30. The company will discuss the results of the completed Phase 2 AKITA study and the continued development plan for the company’s lead candidate RMC-035. New preclinical results from the company's peptide platform will also be presented. In addition to Guard Therapeutics CEO Tobias Agervald and Chief Medical Officer Michael Reusch, Dr. David Goldsmith, Adjunct Professor of Nephrology, King's College, London, will also participate and provide an external perspective on the AKITA results.
The goal of the day is to provide increased understanding of RMC-035 and the recently completed Phase 2 AKITA study, as well as to provide deeper insights into the ongoing development program and the announced phase 2b study scheduled to start in the third quarter of 2024, with the aim of identifying an optimal dosing regimen for the drug candidate ahead of an upcoming pivotal study. The company will also present new results from its preclinical research on potential drug candidates for the treatment of various chronic diseases.
The presentations will be followed by a Q&A session where questions can be submitted.
The presentations will be held in English and will be live streamed via https://www.finwire.tv/webcast/guard-therapeutics/research-update/ and will also be available afterward on Guard Therapeutics' website.
Program:
- Introduction & Meeting Goals (CEO Tobias Agervald)
- Path forward following the Phase 2 AKITA study results and feedback from the FDA (CEO Tobias Agervald)
- Loss of kidney function after open heart surgery: medical need and interpretation of AKITA results (Dr. David Goldsmith, Adjunct Professor of Nephrology, King's College, London)
- Overall clinical development plan including the design of the phase 2b POINTER study (CMO Michael Reusch)
- New results from the company's preclinical peptide platform (CEO Tobias Agervald)
- Q&A